Diclofenac for Prevention of Post-ERC Pancreatitis

Common Bile Duct Diseases Clinical Trial

Official title:

Diclofenac for Prevention of Post-ERC Pancreatitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03595150
• Other study ID #: Post-ERCP-01
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: January 1, 2025
• Est. completion date: December 31, 2027

Study information

• Verified date: April 2024
• Source: Karolinska Institutet
• Contact: Gabriel Sandblom, Ass Prof
• Phone: +46704158218
• Email: gabriel.sandblom[@]ki.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.

Description:

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a procedure commonly performed for diagnosing changes in the bile ducts or managing outflow obstruction. Although ERCP may in most cases be performed safely, there is a risk of developing acute pancreatitis following the procedure. The risk has been estimated to 5-10%, with an increased risk in women, younger patients and in case the cannulation is difficult.

Phospholipase 2 is crucial in the pathogenesis of acute pancreatitis. As Diclofenac is a potent inhibitor of Phospholipase 2, it has been suggested that it may be used for prevention of post-ERCP pancreatitis. There is some evidence for the effectiveness of Diclofenac, but more studies are needed to confirm that it reduces the risk of post-ERCP pancreatitis.

In order to test whether Diclofenac reduces the risk for post-ERCP pancreatitis, a register-based randomized controlled study is planned. The study will be conducted embedded in the Swedish Register for Gallstone Surgery and ERCP (GallRiks). GallRiks includes data corresponding to the eligibility criteria as well as outcome measures. GallRiks will also be used to record which patients have been screened for inclusion.

Patients who meet the eligibility criteria are invited to the study. If they accept inclusion, they are randomized to 100 mg Diclofenac prior to the ERCP or np prophylaxis. No blinding is done.

The aim is to include 1000 patients. When 500 patients have been included, an interim analysis will be performed, comparing the incidence of pancreatitis and mortality in the two groups. A retrospective review of the patient records will be performed for those who develop pancreatitis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients undergoing ERCP

Exclusion Criteria:

• Decision to perform ERCP taken intraoperatively

• Intolerance/allergy against NSAID

• Patients taking NSAID daily

• Severe cardiac fail (ASA>4)

• Kidney failure (GFR<30 ml/min)

• Coagulation disorder

• History of peptic ulcer bleeding

• History of abdominoperineal resection

• Pregnancy

• Patients who do not understand Swedish

Related Conditions & MeSH terms

• Bile Duct Diseases
• Common Bile Duct Diseases
• Pancreatitis

Intervention

Drug:
• Diclofenac
Diclofenac rectally given before the ERCP to prevent pancreatitis

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Karolinska Institutet	Uppsala University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post-ERCP pancreatitis	Acute pancreatitis recorded in GallRiks by responsible endoscopist or surgeon. According to GallRiks criteria pancreatitis includes elevated amylase and abdominal pain of an intensity that hospital stay is warranted.	Within 30 days post-ERCP
Secondary	Adverse drug reactions	Kidney failure, gastroduodenal ulcer or gastrointestinal bleeding	Within 30 days post-ERCP
Secondary	Mortality	Death within 30 days after ERCP	Within 30 days post-ERCP